Faeth Therapeutics has provided a closer look at the pharmacokinetic and pharmacodynamic work behind the dose selected for PIKTOR, its investigational combination of serabelisib and sapanisertib, as the company moves toward one of its most important clinical catalysts of 2026. The analysis supports the regimen being used in the ongoing Phase 2 FTH-PIK-201 study in second-line advanced endometrial cancer, where the company expects topline data by year-end.
The company scheduled the exposure-response analysis for presentation at the 2026 Summit for Novel Therapeutics in Oncology and Precision Medicine in Cancer in New York on August 8. The work integrates pharmacokinetic modeling with skin-biopsy pharmacodynamic information from earlier third-party studies of serabelisib and sapanisertib and was used to support a recommended Phase 2 regimen of 3 mg sapanisertib and 200 mg serabelisib administered three days each week.
The distinction is important. This is not a disclosure of new efficacy results from FTH-PIK-201, and the modeling cannot establish that PIKTOR will produce a clinically meaningful response in the intended endometrial cancer population. Instead, it addresses an earlier and technically important drug-development question: whether the selected exposures provide a defensible basis for testing simultaneous inhibition of PI3K-alpha, mTORC1 and mTORC2 without simply pushing both components toward their respective monotherapy dose limits.
For Faeth Therapeutics, that dosing question sits at the heart of the PIKTOR thesis. Multi-node pathway inhibition sounds attractive biologically, but oncology drug development has repeatedly shown that hitting more targets is useful only when exposure, tolerability and pathway suppression can coexist. The Phase 2 study now has to determine whether the dose-selection logic translates into sufficient clinical activity and an acceptable safety profile.
Why does the PIKTOR PK/PD analysis matter without new Phase 2 efficacy results?
Pharmacokinetic and pharmacodynamic modeling occupies an unglamorous but crucial part of clinical development. Pharmacokinetics describes how drug exposure changes over time, while pharmacodynamics examines what that exposure does biologically. Connecting the two can help developers understand whether increasing exposure actually produces additional target modulation and whether a lower dose may already be reaching a useful portion of the exposure-response curve.
That issue is particularly relevant for PIKTOR because Faeth Therapeutics is not developing serabelisib or sapanisertib as isolated high-dose monotherapies. PIKTOR combines selective PI3K-alpha inhibition through serabelisib with inhibition of mTORC1 and mTORC2 through sapanisertib, creating what the company describes as vertical or multi-node blockade of the PI3K/AKT/mTOR pathway.
The development hypothesis is that simultaneously suppressing several points along the pathway may reduce the ability of tumor signaling to reactivate around a single inhibited node. Faeth is also attempting to achieve that broader inhibition at doses below those historically explored for the individual agents.
Preclinical work published in the British Journal of Cancer in 2025 found that the serabelisib-sapanisertib combination produced stronger pathway suppression than several single-node strategies in endometrial and breast cancer models. Importantly, however, those findings were preclinical. They establish biological rationale rather than evidence that PIKTOR will deliver superior clinical outcomes in patients.
How was the 3 mg sapanisertib and 200 mg serabelisib Phase 2 regimen selected?
The exposure-response work presented by Faeth integrates information from previous clinical experience with the two agents rather than starting from an entirely new molecule with no human exposure history. The selected regimen uses 3 mg of sapanisertib and 200 mg of serabelisib three days per week. In FTH-PIK-201, these agents are being evaluated alongside paclitaxel.
That choice is consistent with earlier Phase 1 work evaluating sapanisertib, serabelisib and weekly paclitaxel in patients with previously treated advanced solid tumors. The published study used a traditional 3+3 dose-escalation design across five dosing cohorts and identified a recommended Phase 2 range that included sapanisertib at 3 mg or 4 mg alongside 200 mg serabelisib and paclitaxel.
Dose selection becomes particularly meaningful because the highest tolerable exposure is not necessarily the optimal biological dose. For targeted therapies, developers increasingly need to show that the regimen produces enough pathway modulation to justify further escalation while avoiding toxicity that could result in dose interruptions, reductions or discontinuations.
Faeth’s latest modeling therefore strengthens the development rationale behind the 3 mg sapanisertib dose. It does not, however, eliminate the need for prospective clinical validation. Modeling based on earlier trials, surrogate tissue measurements and exposure-response relationships may help select a regimen, but only the ongoing target-population study can show whether that regimen produces the desired balance of efficacy and tolerability.
What does the earlier Phase 1 evidence suggest about PIKTOR, and where are the limits?
PIKTOR did not enter Phase 2 solely on the strength of laboratory modeling. Earlier clinical experience with the combination and paclitaxel provided an efficacy signal, although the dataset was small and heterogeneous.
The published Phase 1 study enrolled 19 heavily pretreated patients with ovarian, breast or endometrial cancer. Fifteen were evaluable for efficacy. Across those evaluable patients, investigators reported an objective response rate of 47% and a clinical benefit rate of 73%, with three complete responses, four partial responses and four cases of stable disease lasting more than six months. Median progression-free survival for the overall enrolled population was reported at 11 months at the study data cutoff.
The endometrioid endometrial cancer subgroup subsequently became particularly important to Faeth’s development strategy. Five patients were represented in that subgroup, with three complete responses and one partial response, translating into the frequently cited 80% objective response rate.
That percentage is eye-catching, but the denominator matters far more than the headline. Five patients cannot establish a reliable response-rate estimate for a broader endometrial cancer population. The result is better viewed as a hypothesis-generating signal that justified a more focused Phase 2 study rather than as an efficacy benchmark the current trial should automatically reproduce.
There is also no randomized comparator in that earlier dataset, and the population included several tumor types. The Phase 2 trial therefore represents a substantially more meaningful test of whether the apparent signal can be replicated in a prospectively defined population.
Why is FTH-PIK-201 a more demanding test of Faeth Therapeutics’ multi-node strategy?
FTH-PIK-201, also identified as GOG-3111, is an open-label Phase 2 study evaluating sapanisertib and serabelisib with paclitaxel in advanced or recurrent endometrial cancer. ClinicalTrials.gov lists planned enrollment of approximately 40 participants, while Faeth materials describe a focus on endometrioid disease in the second-line-or-later setting, following pembrolizumab exposure and with PI3K/AKT/mTOR pathway alterations among the eligibility criteria.
Objective response rate is the primary endpoint. Secondary measures include progression-free survival, duration of response, clinical benefit rate, overall survival and safety and tolerability, giving investigators several ways to determine whether an initial tumor response translates into a more durable treatment effect.
That broader endpoint package matters because response rate by itself will not answer every question around PIKTOR. A regimen can generate radiographic responses without delivering durable disease control, while a promising efficacy signal can also be undermined if treatment-related toxicity makes the intended dose difficult to maintain.
Faeth continues to guide toward topline Phase 2 data by year-end 2026. The ClinicalTrials.gov record carries later estimated completion dates for the overall study, so the anticipated 2026 disclosure should be interpreted as a planned topline clinical update rather than completion of every element and follow-up period contained within the registered study.
Could lower-dose multi-node inhibition address a long-standing problem with the PI3K pathway?
The attraction of PIKTOR lies in a familiar problem in targeted oncology. The PI3K/AKT/mTOR pathway contains multiple interconnected signaling nodes and feedback mechanisms, meaning that inhibiting one component can leave other pathways available for continued or reactivated tumor signaling.
Several drugs that inhibit individual components of the pathway are already used in selected cancers, particularly breast cancer. That clinical validation shows the pathway can be therapeutically relevant, but it does not prove that broader multi-node blockade will necessarily produce greater benefit.
Faeth’s strategy is instead built around combining lower doses of two agents that inhibit different nodes. Preclinical research reported that the 3 mg sapanisertib and 200 mg serabelisib clinical combination doses are substantially below the respective doses studied as monotherapies, while still producing extensive pathway inhibition in laboratory models.
If the approach eventually demonstrates meaningful activity with manageable tolerability, that could provide an important validation of dose-efficient multi-node suppression. If the Phase 2 results fail to show sufficient efficacy, however, strong target engagement or elegant pathway biology will not compensate for the clinical outcome.
That is why the PK/PD poster is best viewed as strengthening one link in the PIKTOR development chain rather than validating the entire program.
What safety questions remain around combined PI3K-alpha and mTORC1/2 inhibition?
Safety will be one of the central issues in interpreting FTH-PIK-201. Both the PI3K and mTOR pathways participate in normal metabolic and cellular signaling, so greater pathway suppression can carry consequences outside tumor tissue.
In the earlier 19-patient Phase 1 study, frequently reported grade 3 or 4 toxicities included decreased white blood cells, nonfebrile neutropenia, anemia, hyperglycemia and elevated liver enzymes. The investigators reported that patients in the highest dosing cohort required dose reductions, while a dose-limiting toxicity occurred in that cohort.
These findings do not establish what the safety profile will look like in FTH-PIK-201. The Phase 2 study is using the lower 3 mg sapanisertib dose selected through the clinical and translational program, and its more defined endometrial cancer population may generate a different tolerability profile.
They do demonstrate why dose optimization is integral to the PIKTOR strategy rather than a technical footnote. A multi-node inhibitor that achieves broader pathway suppression but requires repeated treatment interruption would face a difficult clinical development problem. Conversely, evidence that the selected intermittent schedule can maintain biologically relevant exposure while avoiding excessive toxicity would materially strengthen the program.
How does the breast cancer expansion broaden the clinical case for PIKTOR?
Faeth Therapeutics is already extending PIKTOR beyond endometrial cancer. Study FTH-PIK-101 is a Phase 1b/2 trial evaluating PIKTOR in combinations including fulvestrant in patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
The first patient was dosed in April 2026, and Faeth expects interim data during 2027. ClinicalTrials.gov describes the study as an open-label, multicenter dose-escalation program evaluating the safety and preliminary efficacy of sapanisertib and serabelisib with fulvestrant and potentially other anticancer therapies.
That expansion is strategically important because a positive signal across two hormone-sensitive tumor types would provide broader support for Faeth’s multi-node platform thesis. Equally, the breast cancer program introduces a different treatment landscape with established PI3K, AKT and mTOR-targeted options, making eventual differentiation more demanding.
Faeth also enters these clinical milestones with substantially more financial capacity than the company had as a private biotechnology developer. The February 2026 transaction in which Sensei Biotherapeutics acquired Faeth was accompanied by approximately $200 million in gross private-placement proceeds, after which the combined company adopted the Faeth Therapeutics name and began trading on Nasdaq under FTH in June. Management has positioned that financing around advancing PIKTOR through its upcoming clinical catalysts.
Why the year-end FTH-PIK-201 readout matters far more than the dose-modeling poster
Faeth Therapeutics has now assembled several pieces of evidence around PIKTOR: human exposure experience with both components, an early combination study that produced a clinical signal, preclinical work supporting multi-node pathway inhibition, and PK/PD modeling supporting the dose selected for its ongoing Phase 2 program.
The August presentation makes that dose-selection logic more transparent. It helps explain why Faeth is testing 3 mg sapanisertib with 200 mg serabelisib rather than treating Phase 2 simply as an extension of the highest doses explored in earlier development.
But the investment and clinical-development thesis will ultimately hinge on a much simpler question. FTH-PIK-201 needs to show that the regimen produces a sufficiently convincing response profile in its defined advanced endometrial cancer population, that those responses have meaningful durability, and that treatment can be delivered with an acceptable safety burden.
The small endometrioid subgroup from the earlier Phase 1 study created the reason to run that experiment. The new PK/PD analysis explains how Faeth selected the dose with which it is running it. The expected 2026 Phase 2 readout is where the multi-node PIKTOR hypothesis begins to face its first substantially more consequential clinical test.